Help Therapeutics

Dr. Zhang Yanmin from Xi'an Children's Hospital and Help Stem Cell Innovations Co., Ltd. jointly published two research articles describing the establishment of patient-specific iPSC lines. Both iPSC lines carry extremely rare mutations, including Glycogen Storage Disease II involving the GAA gene with two separated point mutations (R608X and E888X) and Catecholaminergic Polymorphic Ventricular Tachycardia involving mutations in the RyR2 gene and SCN10A gene. Being first of its kind, both iPSC lines represent important medical resources for the study of rare pediatric congenital diseases.